Please assess the completion status of the following clinical trial:

Trial Title: In Vivo Alzheimer Proteomics

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Reports written consent, informed and signed by the patient and a trusted person~* Subject member or beneficiary of a social security system~Specific criteria for group 1 and 2B :~* Age between 55 and 85 years old for patients~* Subject with AD or other neurodegenerative disease (frontotemporal dementia, dementia with Lewy bodies, Parkinson disease)~* Subjects with chronic adult hydrocephalus (HCA) requiring depletion lumbar puncture (PL)~Specific criteria for group 2A :~- Adult patient requiring neurosurgery with CSF shunt (subject with brain trauma, acute hydrocephaly) and favorable evolution that allows removal of the shunt~Exclusion Criteria:~* Patient deprived of liberty by judicial or administrative decision~* Major protected by law~* Pregnancy, women of childbearing age with risk of pregnancy, or breast-feeding~* Presence of a transmissible viral disease (HlV, hepatitis B and C)~* Patient included in a clinical trial~* lnadequate cardiac, hepatic or severe renal disfunction~* Disease amino acid metabolism (Leucinose..)~Exclusion Criteria:~* Information clinical and para-clinical insufficient or unavailable~* Patient deprived of liberty by judicial or administrative decision~* Major protected by law~* Pregnancy, women of childbearing age with risk of pregnancy, or breast~* feeding~* Presence of a transmissible viral disease (HIV, hepatitis B and C)~* Patient included in a clinical trial~* Patient exclusion period relative to another protocol or for which the maximum annual compensation of 4500€ has been reached~* Inadequate cardiac, hepatic or severe renal~* Disease amino acid metabolism (Leucinose..)

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): 60 patients (20 probable AD, 20 Parkinson Disease (PK), 20 neurological disease without cognitive degradation)
- Group 2A (Type: EXPERIMENTAL): 20 patients (patients with brain trauma, acute hydrocephaly), with temporary derivation of the CSF
- Group 2B (Type: EXPERIMENTAL): 30 patients (15 probable AD, 15 neurological disease without cognitive degradation)

Based on this trial design, predict the completion outcome and termination type (if applicable).